Hepatitis B virus X protein and TGF-β: partners in the carcinogenic journey of hepatocellular carcinoma

Hepatitis B infection is substantially associated with the development of liver cancer globally, with the prevalence of hepatocellular carcinoma (HCC) cases exceeding 50%. Hepatitis B virus (HBV) encodes the Hepatitis B virus X (HBx) protein, a pleiotropic regulatory protein necessary for the transcription of the HBV covalently closed circular DNA (cccDNA) microchromosome. In previous studies, HBV-associated HCC was revealed to be affected by HBx in multiple signaling pathways, resulting in genetic mutations and epigenetic modifications in proto-oncogenes and tumor suppressor genes. In addition, transforming growth factor-β (TGF-β) has dichotomous potentials at various phases of malignancy as it is a crucial signaling pathway that regulates multiple cellular and physiological processes. In early HCC, TGF-β has a significant antitumor effect, whereas in advanced HCC, it promotes malignant progression. TGF-β interacts with the HBx protein in HCC, regulating the pathogenesis of HCC. This review summarizes the respective and combined functions of HBx and TGB-β in HCC occurrence and development.


Introduction
Liver cancer is a substantial health problem globally, and it is estimated to be the 6 th most frequent tumor and the 3 rd primary reason for cancer mortalities (1).In 2020, approximately 905,700 and 830,200 people were diagnosed and died, respectively, due to this tumor worldwide.Between 2020 and 2040, a 55.0% annual increase in new liver cancer diagnoses is anticipated, with 1.4 million new cases expected (2).Various factors contribute to liver cancer development, including alcohol, metabolic syndrome, type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), aflatoxin B1, and tobacco (3,4).However, HBV is still the most significant cause as it leads to 56% of the cases, according to GLOBOCAN (5).The most common type of liver cancer, HCC, accounts for nearly 75% of all cases (6) (pp1978-2012) .
HBV, a non-cytopathic DNA virus from the Hepadnaviridae family, causes diseases of liver when transmitted through infected blood or body fluids (7).The viral genomes contain relaxed circular DNA (rcDNA), which encodes numerous proteins and can transform into covalently closed circular DNA (cccDNA) in the nucleus (8-10) (Figure 1).
The HBx protein, comprising 154 amino acids and a 17 kDa molecular weight, and the variation in amino acid sequence of HBx protein is more pronounced between different HBV genotypes than within the same HBV genotype (12).It is named after its encoding gene due to unknown homologous proteins (13).HBx is recruited to cccDNA microchromosomes and enhances their transcription as HBV replicates; alongside being necessary for HBV cccDNA transcription/viral replication (14, 15), it is assumed to be involved in hepatocarcinogenesis. HBx is primarily found in the cytoplasm of hepatocytes, with some residing in the nucleus.HBx activates transcription by interacting with nuclear transcription factors (TFs) while indirectly bound to DNA.Additionally, HBx functions as an adaptor or kinase activator that influences signal transduction pathways (16,17).
As stated, TGF-b and HBx are expressed abnormally in HCC and contribute to its development and progression.HBx expression was positively correlated to TGF-b activity in hepatocytes of cirrhotic/cancerous/chronic hepatitis patients.The results suggested that HBx expression might induce TGF-b1 expression in early-stage HBV infection (25).Additionally, HBx regulates the transition of tumor-suppressive pSmad3C signaling to oncogenic pSmad3L signaling (26), deeming necessary evidence that HBx is intensely contributing to TGF-b carcinogenic effect in HCC.
In the following section, we will examine the specific mechanisms of action of HBx and TGF-b in the progression of HBV-associated HCC and their complex functional cross-talk and interactions.
HBV genome map.HBV comprises a small, partially ~dsDNA genome (the inner blue circle), which contains four promoters and two enhancer regions (Enh1/2), in addition to two direct repeats (DR1/2).The four HBV-coded overlapping ORFs: preS/S, precore/C, polymerase, and X, are indicated by the colored arrows.When the virus is replicating, the rcDNA enters the nucleus, it undergoes conversion into cccDNA through the action of host DNA polymerase and repair enzymes, that act as the viral transcription template, showing the primary HBV transcripts (outer black lines), their 5′ initiation sites (black arrowheads), aside with 3′ poly-A tails (AAAA).(Thisfigure is modified from Figure 1 of the article PMID: 35648301) (11).2).

HBx regulatory signaling pathway leads to HCC
HBx is a key player in the etiology of HCC and manipulates various biochemical pathways within host cells, which are vital for physiological and biochemical functions.HBx redirects these pathways to promote cell proliferation and invasion, impair DNA repair, and evade immune responses, collectively contributing to tumorigenesis.
In particular, the Wnt/b-catenin, Notch signaling pathways, and the insulin-like growth factor (IN/IGF) pathway have been associated with the organization of HBx's carcinogenic influence.The Wnt/b-catenin pathway is upregulated in over 90% of HCC cases (67), it is activated via HBx ectopic expression combined with Wnt-1, nevertheless, this activation is crucial for stabilizing the effect of HBx on b-catenin (27).In turn, the inhibition of Wnt/bcatenin pathway antagonists, SFRP1 and SFRP5, by HBx increases HCC cell proliferation and epithelial-mesenchymal transition (EMT) (28).Concurrently, HBx also leads to prolonged activation of the oncogenic pathway Notch by upregulating its receptors and ligands, particularly Notch-1 and Jagged-1 (29,30).This Notch pathway activation is further amplified by HBx's effect on the Erk (MEK1/2) and PI3K/AKT pathways (68).Furthermore, HBx alters the IN/IGF pathway, which acts in tandem with the Wnt/b-catenin pathway.IN a double-transgene mouse model of HBx and IRS1 that mimic human hepatocellular carcinoma, persistent activation and cross-talk of IN/IGF1, WNT/b-catenin, and Notch enhance HCC cell metastasis and invasiveness, and up-regulation of aspartate bhydroxylase (ASPH) is central to these signaling cascades (31).The above mechanism exploration is primarily based on mouse models HBx also compromises DNA repair, a critical tumorigenic facet of HBV-induced HCC.The HBx protein can impede the repair of damaged DNA mediated by the anti-oncogene p53 (32), inhibition of transcription factor IIH (TFIIH) (33), and degradation of Smc5/6 complex (34).This disruption of DNA repair processes leads to the accumulation of DNA damage, subsequently instigating the onset of hepatocarcinogenesis.
On the immune evasion front, HBx uses several strategies to avoid the innate immune response, particularly suppression of interferons.It suppresses Toll-like receptor 3 (TLR3) and its adaptor protein, TIR-domain containing adaptor protein inducing interferon-b (TRIF), thereby reducing the anti-HBV immune responsee (35).Furthermore, HBx inhibits interferon b (IFN-b) signaling by interacting with IPS-1, suppressing interferon induction during HBV infection (36).Moreover, HBx facilitates adenosine deaminases acting on RNA 1 (ADAR1)-mediated viral RNA editing, which prevents the recognition of HBV RNA by pattern recognition receptors, thereby inhibiting interferon production (37).Patients with HBV immune tolerance experience a higher incidence of HCC compared to those who receive immune activation therapy (69).Type I interferons are approved as a firstline treatment for chronic HBV.However, it is speculated that the effectiveness of IFN therapy may be limited due to inhibition by HBx, and its significant side effects limit its broader clinical application.Thus, there is a need to develop more effective immunotherapeutic drugs to curb the progression of HBVassociated HCC.

HBx causes HCC through epigenetic mechanisms
In the context of HBV or HCV infection, HCC development and progression are supported by epigenetic dynamics.This is associated with DNA methylation, histone modifications, microRNAs (miRNAs), and long noncoding RNAs (lncRNAs).
In liver tissue affected by chronic hepatitis or cirrhosis due to HBV or HCV infection, DNA methylation can be detected, which is considered a precancerous state of HCC (70).Significantly elevated HBx expression is associated with methylation abnormalities in HBV-infected HCC patients (38).DNMT1, responsible for maintaining DNA methylation during replication, and DNMT3A/ 3B, also known as de novo methyltransferases, are involved in methylation modifications (11).HBx upregulates DNMT1/3A1/ 3A2, resulting in the hypermethylation of tumor suppressorrelated genes (38,39), such as increasing CpG island methylation of the cytokine signaling-1 (SOCS-1) promoter (41) and hypermethylation of p14's promoter (42).HBx also inhibits Tyrosine-protein phosphatase nonreceptor type 13 (PTPN13) transcription by upregulating DNMT3A and promoting DNA methylation, thereby facilitating the progression of HCC progression (40).HBx and its multifunctional roles in hepatocarcinogenesis. HBx interacts with several cellular targets through various mechanisms, including affecting multiple signaling pathways, damaged DNA repair, immune evasion, and epigenetic changes (DNA methylation, histone acetylation, ncRNAs) to accelerate HBV transcription, replication, and malignant progression of HCC.

HBx mutation leads to HCC progression
HBV DNA integration into the host genome induces genomic instability and direct insertion mutations in cancer-related genes in early-stage clonal HCC expansion (82).Variation in the HBx sequence, specifically at the 3'-terminus, substantially affects the HCC development.Chimeric transcripts of HBx and human genes, often including 3'-terminal deletions, are frequently expressed and can encode alternative HBx versions implicated in transcriptional regulation (83,84).

Therapeutic approach for HBx
Currently, there is a lack of drugs and therapeutic methods targeting HBx, which awaits further development by researchers.During HBV infection, the host SMC complex, SMC5/6, suppresses viral transcription.HBx promotes ubiquitination and degradation of SMC5/6, enhancing cccDNA transcription and increasing viral replication.This destabilization of SMC5/6 aids HBV in evading host immune surveillance and facilitates viral persistence and propagation (15,88,89).Nitazoxanide, an FDA-approved thiazolide antimicrobial for protozoal enteritis, and Pevonedistat, an NAE inhibitor approved for myelodysplastic syndromes, have demonstrated in vitro efficacy in inhibiting the HBx/SMC5/6 axis.This inhibition restores SMC5/6 protein levels, effectively suppressing HBV transcription and translation (90)(91)(92).Dicoumarol, the precursor to warfarin and a competitive NQO1 inhibitor, reduces HBx level and cccDNA transcription in both HBV-infected hepatocytes and humanized mouse models (93).

TGF-b 3.1 Overview of the TGF-b Signaling
The TGF-b branch, classified as the TGF-b family, is activated by three ligands: TGF-b1-3, with TGF-b1 being the most abundant and typical isomer as it is secreted by almost all cells (94).The TGFb ligand synthesis is in a longer precursor protein that is cleaved by furin protease; additionally, TGF-b disulfide-bonded dimers and the latency-associated peptide (LAP) are joined by non-covalent bonds to form a small latent complex, which is cross-linked with the latent TGF-b binding protein (LTBP) forming a large latent complex.This inactive complex is then secreted and associated with the extracellular matrix (ECM) (95).Activation occurs when particular signals initiate the release of active TGF-b from the complex, involving elements such as extreme pH, proteases, and integrins (96).Upon TGF-b ligand binding, TbRII dimerizes and recruits TbRI to produce a heterotetrameric TbRI-TbRII complex (97,98).

TGF-b Signaling in HCC
TGF-b signaling is essential at every stage of liver disease progression, from initial inflammation and damage to fibrosis, cirrhosis, and ultimately liver cancer.Early on, it inhibits tumor growth by inducing senescence and apoptosis.It promotes tumor growth, EMT, and metastasis in advanced stages.Nevertheless, Smad-dependent and independent pathways are involved in the complex signaling (106).(Figure 4).

Cellular senescence
Cellular senescence is a persistent cell cycle arrest state inhibiting tumor progression (117)(118)(119).There is a significant relationship between tumor inhibition and cell senescence in HCC.Telomerase and telomeres are mainly involved in malignant cell senescence and hepatocyte aging (120), with telomerase reactivation promoting uncontrolled proliferation and malignant transformation in HCC (121).In malignant tumors, TGF-b/Smad signaling inhibits human telomerase reverse transcriptase (hTERT), demonstrating a regulatory role for TGFb in HCC cell senescence (122-124).

Autophagy
Autophagy is responsible for the degradation of proteins and cells (125,126).Through Smad and non-Smad pathways, TGF-b induces autophagy in HCC cells by upregulating the expression of autophagy-related genes, including BECLIN1, ATG5, ATG7, and DAPK.Autophagy is closely related to TGF-b-mediated growth inhibition of HCC cells.Autophagy gene knockdown reduces TGFb-mediated growth suppression and decreases pro-apoptotic gene expression.HCC cells are more resistant to TGF-b-induced autophagy than breast cancer cells, indicating its significance in growth suppression (127, 128).However, recent studies have found that tumor cells in HCC rely on autophagy for survival.This process can promote tumor development by inducing autophagic cell death in liver (129, 130).Therefore, the role of TGF-b-induced autophagy in liver cancer requires further research to clarify.

Apoptosis
In liver cells, TGF-b induces apoptosis and inhibits cell proliferation (131).It initiates apoptosis through the death receptor pathway by mediating the activation of the TNF-related apoptosis-inducing ligand (TRAIL) promoter's AP-1 site via Jun, Fos, and Smad proteins (132) (p1) , (133).TGF-b can induce apoptosis in liver cancer cells via the mitochondrial and death receptor pathways.TGF-b can also induce apoptosis via the mitochondrial pathway by reducing the expression of antiapoptotic B-cell lymphoma 2 (Bcl-2) family proteins and activating caspases (134).ROS generation via NADPH oxidase is essential for TGF-b-induced HCC cell apoptosis (135, 136).The apoptotic response can be suppressed by the epidermal growth factor receptor (EGFR) pathway (137, 138).

Cancer cell proliferation
Most malignant tumors exhibit an increase in cell proliferation.TGF-promotes HCC proliferation via several pathways.Through the EGFR, TGF-b activates Ras/Erk, PI3K/AKT, and STAT3 signaling, resulting in hepatocyte proliferation.In addition, it upregulates the expression of PDGF to activate the PI3K and bcatenin pathways.TGF-b also activates other pathways, such as Wnt/b-catenin, Snail, and GLI-1, contributing to cancer cell proliferation (139)(140)(141)(142)(143). Furthermore, TGF-b/SMAD2 signaling induces c-KIT receptor ligand (stem cell factor) expression, activating c-KIT/JAK1/STAT3 signaling and establishing a positive feedback loop for HCC proliferation (139).The p38 and PI3K/AKT pathways mediate the PRL-3-induced TGF-b1 by activating FAK and developing another positive feedback loop (144).Thus, TGF-b interacts with multiple carcinogenic pathways in tumors, and blocking TGF-b activation could serve as a vital approach in the treatment of liver cancer.

Genetic alteration and epigenetic modification
HCC development involves genetic, epigenetic, and transcriptomic mechanisms.Approximately 40% of HCC cases contain mutations in TGF-b pathway genes.Overexpression of TGF-b pathway genes is associated with inflammation and fibrosis, whereas their down-regulation inhibits tumor growth (145).Several TGF-b target genes implicated in HCC are overexpressed, including VEGFA, COL4A1, SNAI2, DAPK2/3, CDKN1A, and CDKN1.Genomic instability in HCC is caused by mutations in the TGF-b pathway and its non-canonical targets, including the JNK/MAPK/ IKK, ERK/MAPK, RHO-ROCK, and PI3K/AKT pathways (146).
Epigenetic modifications increase the carcinogenic influence of TGF-b on HCC.In early HCC, demethylation of the Smad4's promoter suppresses tumor growth, whereas hypomethylation of Smad7 and SNAI1 in the promoter region facilitates EMT recurrence and metastasis, it has been reported that the use of decitabine may drive liver cancer progression towards a procarcinogenic direction through this pathway (147).Methylation of the TTP promoter eliminates the post-transcriptional regulatory function of c-Myc, shifting TGF-b signaling from proliferation inhibition to promotion (148,149).In HCC, high methylation levels frequently lead to the inactivation of the tumor suppressors RUNX3 and Smad Interacting Protein-1 (SIP1), which interact with Smads (150, 151).In conjunction with HDACs and G9 methyltransferase, the TGF-b-induced overexpression of SNAIL2 suppresses E-cadherin and enhances the invasiveness and metastasis of HCC cells (152).

Immune suppression
TGF-b, by modulating immune cells involved in immune homeostasis and tolerance, acts as a critical inhibitor of both adaptive and innate immunity.This creates an immunosuppressive tumor microenvironment that facilitates tumor progression (161).Induction and differentiation of liver Treg cells by TGF-b contribute to immunosuppression (162) via numerous cell types, such as LSECs, HSCs, CAFs, TAMs, and MDSCs.Treg cells suppress immune responses, enhance cell proliferation, and deplete cytotoxic T lymphocytes (CTLs).TGF-b upregulates PD-1 and PD-L1, inhibiting TCR signaling and T cell proliferation and leading to T cell depletion in HCC (146).In addition to inhibition of T cells, TGFb increases alternative macrophage activation by enhancing Tim-3 transcription in tumor-associated macrophages (TAMs), leading to the growth of HCC (163).

Interaction of HBx and TGF-b in HCC
As described previously, HBx and TGF-b play distinct functions in HBV-HCC progression.In fact, HBx was shown to induce TGF-b expression early in HBV infection (25).Meanwhile, TGF-b can increase signaling pathway proteins in HBx pathogenesis (181), suggesting that TGF-b and HBx co-regulate specific signaling pathways that promote HCC.Additionally, regulating multiple pathways and epigenetic and genetic events by HBx mediates TGF-b's participation in distinct ways in HBV-HCC progress pathogenetic mechanism.
It has been demonstrated that HBx overexpression induces the development of hepatic tumors by stimulating DNA synthesis (210).Studies have revealed that HBx shifts TGF-b signaling from the TbRI-dependent pSmad3C tumor-suppressive pathway to the JNKdependent pSmad3L oncogenic pathway during carcinogenesis, as observed in biopsy samples from chronically HBV-infected patients and HBx transgenic mice with liver lesions (26).The proto-oncogene c-Myc, a target of TGF-b/SMAD signaling (211, 212), is involved in HCC malignant progression (213).pSmad3L/Smad4 triggers c-Myc transcription, whereas pSmad3C/Smad4 inhibits it.The two complexes antagonize each other and govern c-Myc expression.HBx's presence may cause the signal to upregulate c-Myc and promote cancer cell growth (214) (Figure 5).
In conclusion, the interaction between HBx and TGF-b plays an essential role in hepatocarcinogenesis at various stages of HBV infection.TGF-b signaling has a dual function, promoting tumor suppression in the early stages of tumorigenesis while promoting tumor growth in advanced malignancies.Smad3's function is determined by its phosphorylation status, with C-terminally phosphorylated Smad3 (pSmad3C) functioning as a tumor suppressor and linker-phosphorylated Smad3 (pSmad3L) contributing to oncogenesis.HBx modifies the TGF-b signaling pathway, redirecting it to the oncogenic pSmad3L pathway.This perturbation promotes the progression of the cell cycle, inhibits apoptosis, and accelerates the development of hepatocellular carcinoma.

Other HBx effects on TGF-b signaling
In prior studies, researchers revealed a correlation between HBx and TGF-b expression in HBV-infected cells.TGF-b1 level correlates positively with HBx protein expression in early-stage HBV infection, suggesting that HBx may directly or indirectly promote TGF-b1 expression.HBx forms a complex with Egr-1 protein and transactivates the TGF-b1 promoter via the Egr-1 binding site (25).HBx overexpression during HBV infection correlates with the release of secreted factors, particularly TGFb, from HBx-transfected HCC cells or adjacent endothelial cells through increased CD133 expression, which induces invasion of these cells by EMT (210).
TGF-b1 inhibited cell proliferation and invasion in a study involving trophoblast cells (HTR-8/SVneo).Nevertheless, HBx activated the Smad pathway in HBx-transfected cells, resulting in the downregulation of E-cadherin and the upregulation of vimentin and N-cadherin, which reduced the apoptotic capacity and increased the invasive capacity of HTR-8/SVneo cells.The mechanism by which HBx shifts TGF-b signaling in HTR-8/ SVneo cells needs additional investigation (211).Additionally, HBx inhibits the expression of the E-cadherin gene (CDH1) by activating TGF-b, which may be an additional mechanism for its downregulation of E-cadherin and promotion of tumor metastasis (212).The HTR-8/SVneo cell line is derived from cells that were grown from early human placental chorionic villi explants and transfected with a gene encoding the Simian Virus 40 large T antigen.Since it is not sourced from a liver cancer cell line, further foundational experiments are necessary to determine whether it can represent the general mechanisms within HBV-infected and liver cancer patients.This includes using human-derived liver cancer cell lines and replicating the studies in mouse models that simulate liver cancer to validate the results.
In an HBx transgenic mouse model undergoing partial hepatectomy, TGF-b, Smad2, and phosphorylated Smad3/4 (ser423/425) were significantly overexpressed in the HBx transgenic mice liver compared to non-transgenic mice, indicating the impact of HBx on the TGF-b/Smad pathway, which promotes the progression of HCC (213).Furthermore, HBx disrupts the negative feedback loop between TGF-b and protein phosphatase magnesium-dependent 1A (PPM1A) by enhancing PPM1A ubiquitination and degradation, resulting in TGF-b pathway overactivation, HCC migration, and invasion (219).HBx also stabilizes the binding of the Smad complex to the transcriptional machinery and facilitates the nuclear transposition of Smads, thereby amplifying TGF-b signaling (220).
Contrary to previous findings, some studies suggest a negative correlation between HBx and TGF-b activation.For example, HBx inhibits TGF-b-induced apoptosis by linking Src to PI3K, thereby activating the PI3K/Akt signaling pathway (221, 222).And another study showed that cells transfected with HBx exhibited reduced expression of the TGF-b type II receptor, resulting in a weaker TGF-b1 response and reduced growth inhibition in response to TGF-b1 (214).Furthermore, It is evident that the TGF-b signaling pathway is primarily influenced and regulated by HBx, particularly within HBV-infected cells.It is worth noting that HBx has been shown to lead to malignant transformation of HCC by influencing dysregulation of TGFB and thereby activating multiple cancer-promoting mechanisms.including EMT, anti-apoptosis, proliferation, inflammatory responses, metastasis, invasion, and fibrosis.Therefore, researchers need to pay more attention to the interaction mechanism of these HBx-TGF-b axis, and develop anti-tumor drugs that can target the common pathway of this axis, bringing new hope to the drug treatment of hepatocellular carcinoma.(Figure 6).

Conclusion and discussion
The incidence and mortality rates of liver cancer have garnered widespread attention within the academic community.With the advancement of liver cancer research, there has been a deeper understanding and significant progress in elucidating carcinogenic molecular mechanisms.Various mechanisms, such as DNA damage, immune evasion, epigenetic alterations, and genomic mutations, have been emphasized in studies and are considered crucial in promoting HCC through HBx.Notably, as a key signaling pathway, TGF-b plays dual roles in HCC, transitioning from an early anticancer effect to a late pro-cancer effect.HCC can acquire invasive tumor characteristics such as EMT and aberrant proliferation through this pathway.In numerous recent studies, it has been demonstrated that HBx and TGF-b signals interfere and interact with one another in HCC and collectively regulate HCC progression.With future technological advances, it is believed that more in-depth studies will be necessary to reveal the HBx oncogenic mechanism, a star protein, and TGF-b, a potential HCC therapeutic target, and to design effective clinical management strategies for HBV-correlated HCC patients.In the near future, these efforts will provide HCC patients with more effective and sensible options for receiving targeted therapies.

3. 2 . 1
Tumor suppressor roles of TGF-b in HCC 3.2.1.1 Cell cycle arrest TGF-b induces HCC cell cycle arrest by suppressing transcriptional factor expression, including the pro-growth TF c-Myc, which is mediated through nuclear translocation of a complex consisting of Smad3, E2F4, or E2F5, and RB-related factor p107 (107, 108).It also regulates cyclin-dependent kinases (CDKs) and their inhibitors, leading to G1 arrest (109).CDK2 binds to cyclin E to drive the cell cycle, while CDK4 or CDK6 binds to cyclin D (110).Furthermore, TGF-b reduces the inhibitory effects of c-Myc on CDK inhibitors p21CIP1 and p15INK4B, leading to cell cycle arrest (111-113) (p1) , (114).The accumulation of NADPH oxidase-4 (Nox4) and ROS in well-differentiated HCC cell lines further enhances the expression of TGF-b-induced p21CIP1 and

FIGURE 4 TGF
FIGURE 4 TGF-b dichotomous role in HCC development and progression.TGF-b has various tumor-suppressing functions, including G1 and G2 cell cycle arrest, cellular senescence, autophagy, and apoptosis.Conversely, it has the ability to serve as a tumor promoter, inducing cancer cell proliferation, EMT, and immune suppression in HCC.

FIGURE 5
FIGURE 5HBx participated in the conversion of dichotomous effects on HCC in the TGF-b pathway.JNK-activated pSmad2/3L-mediated cell proliferation signal and TbRI-activated pSmad2/3C-mediated cell cycle arrest signal are mutually antagonistic.HBx leads TGF-b signaling in hepatocytes to shift from the TbRI-dependent pSmad3C tumor-suppressive pathway to the JNK-dependent pSmad3L oncogenic pathway during carcinogenic stages.
spindle-associated protein 1 HPIP hematopoietic pre-B cell leukemia TF-interacting protein lncRNA long non-coding RNA

TABLE 1 A
summary of the mechanisms by which HBx leads to HCC.